PRESS RELEASE
REGULATED INFORMATION
Publication of transparency notifications
Liège (Belgium), 31 July 2020, 16h30 (CEST) – regulated information – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Hyloris Pharmaceuticals SA/NV publishes the following information:
Stijn Van Rompay has announced that, on 31 July 2020, he held 6.824.304 shares, representing 26,42% of the total number of voting rights (25.832.632).
The notification dated 31 July 2020 contains the following information:
- Reason for the notification:
- Acquisition or disposal of voting securities or voting rights
- Acquisition or disposal of financial instruments that are treated as voting securities
- Notification by: a person that notifies alone
- Persons subject to the notification requirement: Stijn Van Rompay
- Transaction date: 31 July 2020
- Threshold that is crossed: 25%
- Denominator: 25.832.632
- Notified details:
| A) Voting rights | Previous notification | After the transaction | |||
| # of voting rights | # of voting rights | % of voting rights | |||
| Holders of voting rights | Linked to securities | Not linked to the securities | Linked to securities | Not linked to the securities | |
| Stijn Van Rompay | 5.849.338 | 6.824.304 | 26,42% | ||
| TOTAL | 6.824.304 | 0 | 26,42% | 0,00% | |
| TOTAL (A & B) | # of voting rights | % of voting rights |
| 6.824.304 | 26,42% |
- Additional information: The repayment of the stock lending agreement took place on 31 July 2020. The call option was exercised in respect of 112.466 shares and expired for the remainder on 29 July 2020.
-Ends-
For more information, please contact: Hyloris Pharmaceuticals
Stijn Van Rompay, CEO Koenraad Van der Elst, CLO
+32 (0)4 346 02 07
contact@hyloris.com
About Hyloris Pharmaceuticals SA/NV
Based in Liège, Belgium, Hyloris is an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system. Hyloris’ portfolio spans three areas of focus: IV Cardiovascular, Other Reformulations and Established Market (high-barrier generics). Hyloris currently has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, commercialized through its partner AltaThera, and Maxigesic® IV, a non-opioid analgesic product for the treatment of pain, developed with the Company’s partner, AFT Pharmaceuticals. Additionally, Hyloris has 12 product candidates in various stages of development across the Company’s wider portfolio. Read more at www.hyloris.com. Hyloris stands for “high yield, lower risk” and relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.
Attachment
